ZEO ScientifiX (ZEOX) plans to expand its commercial and provider-support operations into Georgia and Tennessee as new state regenerative medicine laws take effect.
The company aims to help healthcare professionals navigate Georgia HB 1275 and Tennessee HB 2246, which set requirements for certain stem cell and regenerative medicine therapies, including product sourcing, documentation, informed consent, scope of practice, and safety oversight. ZEO ScientifiX intends to offer regenerative biologics, quality and manufacturing documentation, physician education, and clinical collaboration, using an adaptable model built from its Florida experience to scale as more states adopt similar frameworks.
ZEO ScientifiX (OTCQB:ZEOX) has announced the multidisciplinary faculty and guest speaker lineup for the inaugural ZEO Xperience, a three-day regenerative medicine event for healthcare professionals to be held October 23-25, 2026, at Pier Sixty-Six Resort + Marina in Fort Lauderdale, Florida.
The program will combine classroom education with hands-on clinical training on October 24, led by specialized faculty in aesthetics, orthopedics, intimate health, and regenerative plastic surgery. According to ZEO ScientifiX, attendance will be limited to encourage interaction, and registration is open with full-event and single-day options.
ZEO ScientifiX (OTCQB:ZEOX) has launched ZEO Xperience, a three-day immersive regenerative medicine educational event for licensed healthcare professionals, to be held October 23-25, 2026, at the newly reimagined Pier Sixty-Six Resort in Fort Lauderdale, Florida.
The inaugural ZEO Xperience combines evidence-based education in regenerative biologics, hands-on clinical training, practice growth strategies, and exposure to emerging technologies. Programming is organized into three themed days: Science & Innovation, Clinical Training & Practice Growth, and a Biohacking Experience focused on performance optimization and wellness technologies. Attendance is intentionally limited to foster interaction and collaboration, and registration is now open via the company’s website.
ZEO ScientifiX (OTCQB:ZEOX) highlights its role in South Florida’s biotechnology ecosystem from its base at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida. The company focuses on regenerative biologic research, development, manufacturing, and physician education as interest in regenerative medicine grows across multiple specialties.
According to ZEO ScientifiX, its strategy centers on building a stronger bridge between scientific advancement and clinical practice through physician Master Classes, webinars, scientific programming, professional collaborations, and an expanded Medical Advisory Board. The company plans to continue expanding scientific and educational initiatives and deepen relationships across the medical community to support responsible advancement of regenerative medicine in Florida’s emerging life sciences hub.
ZEO ScientifiX (OTCQB:ZEOX) reported sharp revenue growth for the quarter and six months ended April 30, 2026. Quarterly revenue rose 124.6% to $2.58 million, while six-month revenue increased 79.9% to $4.03 million, mainly from allogenic biologic products.
The company maintained approximately 80% gross margins for the six-month periods in 2026 and 2025 and reduced its six-month net loss to about $1.0 million from $2.6 million a year earlier, reflecting expanding demand, higher physician adoption, and broader awareness of its regenerative biologics portfolio.
ZEO ScientifiX (OTCQB:ZEOX) will host a live virtual educational webinar for healthcare professionals titled “One Year Later, Three States Stronger: The Southeast Regen Revolution” on July 22, 2026 at 6:45 p.m. ET.
The session will review Florida’s first year under its stem cell law, discuss new laws in Tennessee and Georgia, and offer scientific, medical, and regulatory perspectives on expanding regenerative medicine access across the Southeast.
ZEO ScientifiX (OTCQB:ZEOX) supported a 10-day pediatric burn reconstruction mission in Cusco, Peru by donating regenerative biologic products used by Medical Advisory Board member Dr. Constantino Mendieta.
The team evaluated about 80 children and performed nearly 40 reconstructive surgeries, aligning with ZEO ScientifiX’s focus on physician-led care and regenerative medicine education.
ZEO ScientifiX (OTCQB:ZEOX) expanded its Medical Advisory Board by adding nine physicians and scientific innovators in regenerative and longevity medicine. The board now spans orthopedics, oncology, longevity, pain management, plastic surgery, and advanced biologic therapies, supporting clinical protocols, product standards, and physician education.
Advisors will guide scientific development, serve as faculty for educational programs such as the Physician-Led Patient Masterclass, and contribute to initiatives including the XPRIZE Healthspan longevity prize competition, where ZEO ScientifiX was selected as a $101 million semi-finalist.
ZEO ScientifiX (OTCQB:ZEOX) launched a Physician-Led Patient Masterclass program on May 27, 2026, to help doctors educate patients on regenerative medicine. The initiative builds on training over 600 physicians across the Southeast in stem cell use for Florida-permitted indications: pain management, wound care, and orthopedics.
The program formalizes a successful Vero Beach pilot led by Dr. Alita Sikora and focuses on physician-hosted events, safety, product sourcing standards, and informed patient decision-making.
ZEO ScientifiX (OTCQB:ZEOX) reported that unaudited monthly sales surpassed $1.0 million in April 2026, the first time it has reached this level. Management views this as a key growth inflection, driven by a newly built internal sales force and physician education masterclass programs supporting regenerative medicine clinics.